Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 13, 2024

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX for Metastatic Pancreatic Adenocarcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study
J. Clin. Oncol 2024 Jan 17;[EPub Ahead of Print], C De La Fouchardière, D Malka, C Cropet, S Chabaud, J Raimbourg, D Botsen, S Launay, L Evesque, A Vienot, H Perrier, M Jary, Y Rinaldi, C Coutzac, JB Bachet, C Neuzillet, N Williet, R Desgrippes, T Grainville, T Aparicio, A Peytier, T Lecomte, GS Roth, A Thirot-Bidault, N Lachaux, O Bouché, F Ghiringhelli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading